Methods for increasing efficacy of lipid formulated siRNA
View Patent ↗This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
1. A kit comprising (1) a first effective unit dosage form of a neutral liposomal formulated siRNA targeting a PCSK9 gene; and (2) a second effective unit dosage form of the neutral liposomal formulated siRNA targeting a PCSK9 gene, wherein the first effective unit dosage form is effective to increase LDLR levels in a human, and wherein the second effective unit dosage form is less than the first effective unit dosage form.
2. The kit of claim 1 , wherein the neutral liposomal formulated siRNA is MC3, SNALP or XTC-2 formulated.
3. The kit of claim 1 , wherein the neutral liposomal formulated siRNA comprises ApoE.
4. The kit of claim 1 , wherein the neutral liposomal formulated siRNA is XTC-2 formulated.
5. The kit of claim 1 , wherein the neutral liposomal formulated siRNA targets a PCSK9 gene and comprises a sense strand and an antisense strand and the antisense strand comprises at least 15 contiguous nucleotides of AD-10792 antisense strand.
6. The kit of claim 1 , wherein the neutral liposomal formulated siRNA comprises AD-10792.
7. The kit of claim 1 , wherein the first effective unit dosage form is effective to lower total serum cholesterol levels in a human by at least 15%.
8. The kit of claim 7 , wherein the second effective unit dosage form is effective to maintain the lowered total serum cholesterol levels.
9. The kit of claim 1 , wherein the second effective unit dosage form is at least two fold less than an effective unit dosage form of the neutral liposomal formulated siRNA targeting a PCSK9 gene that would be administered to a subject without the first effective unit dosage form.